The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC

Cisplatin is one of the most common chemotherapeutic drugs for non-small cell lung cancer (NSCLC). However, the response rate is limited because of drug resistance. Histone deacetylase inhibitors (HDACis), which can alter DNA accessibility by regulating chromatin structure and inducing apoptosis, ex...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Cai, Yang, Yan, Xiang, Zhang, Guoqing, Zhao, Weihong, Jiao, Shunchang
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2015
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4662470/
https://ncbi.nlm.nih.gov/pubmed/25944617
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia